Follow the people · Insider
Steve Pakola
Steve Pakola files insider transactions with the SEC as a chief medical officer of Regenxbio (RGNX). We hold 5 disclosed purchases and sales filed since 25 April 2018, 3 of them in the last 90 days.
- Files forRGNX
- Disclosed buys and sells5 in all, 3 in the last 90 days
- Last disclosure4 August 2026
Positions held
2 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 17 April 2019 — 1 August 2026Chief Medical Officer · Regenxbio (RGNX)43 Form 4 lines · source: SEC Form 4
- Filed 23 April 2018 — 15 February 2019Chief Medical Officer · Aerpio Pharmaceuticals (ARPO)2 Form 4 lines · source: SEC Form 4
Everything they disclosed
45 entries, newest first — one per disclosure report, one per Form 4 line- had shares withheld for tax on 7,468 shares of RegenxbioSEC Form 44 August 2026Common Stock · traded 1 August 2026 · filed 4 August 2026
- exercised options over 2,161 shares of RegenxbioSEC Form 46 July 2026Common Stock · traded 2 July 2026 · filed 6 July 2026
- ▼ sold on the open market 2,161 shares of RegenxbioSEC Form 46 July 2026Common Stock · traded 2 July 2026 · filed 6 July 2026
- exercised options over 2,161 shares of Regenxbio (a derivative holding)SEC Form 46 July 2026Stock Options (Right to Buy) · traded 2 July 2026 · filed 6 July 2026
- ▼ sold on the open market 19,608 shares of RegenxbioSEC Form 41 July 2026Common Stock · traded 29 June 2026 · filed 1 July 2026
- exercised options over 36,725 shares of RegenxbioSEC Form 41 July 2026Common Stock · traded 1 July 2026 · filed 1 July 2026
- ▼ sold on the open market 36,725 shares of RegenxbioSEC Form 41 July 2026Common Stock · traded 1 July 2026 · filed 1 July 2026
- exercised options over 36,725 shares of Regenxbio (a derivative holding)SEC Form 41 July 2026Stock Options (Right to Buy) · traded 1 July 2026 · filed 1 July 2026
- ▼ sold on the open market 15,309 shares of RegenxbioSEC Form 413 May 2026Common Stock · traded 11 May 2026 · filed 13 May 2026
- ▼ sold on the open market 5,124 shares of RegenxbioSEC Form 412 March 2026Common Stock · traded 10 March 2026 · filed 12 March 2026
- ▼ sold on the open market 5,124 shares of RegenxbioSEC Form 412 March 2026Common Stock · traded 10 March 2026 · filed 12 March 2026
- had shares withheld for tax on 5,267 shares of RegenxbioSEC Form 43 February 2026Common Stock · traded 1 February 2026 · filed 3 February 2026
- had shares withheld for tax on 5,267 shares of RegenxbioSEC Form 43 February 2026Common Stock · traded 1 February 2026 · filed 3 February 2026
- was granted 65,847 shares of RegenxbioSEC Form 48 January 2026Common Stock · traded 6 January 2026 · filed 8 January 2026
- was granted 35,402 shares of Regenxbio (a derivative holding)SEC Form 48 January 2026Stock Options (Right to buy) · traded 6 January 2026 · filed 8 January 2026
- was granted 35,402 shares of Regenxbio (a derivative holding)SEC Form 48 January 2026Stock Options (Right to buy) · traded 6 January 2026 · filed 8 January 2026
- was granted 65,847 shares of RegenxbioSEC Form 48 January 2026Common Stock · traded 6 January 2026 · filed 8 January 2026
- had shares withheld for tax on 18,247 shares of RegenxbioSEC Form 46 January 2026Common Stock · traded 2 January 2026 · filed 6 January 2026
- had shares withheld for tax on 18,247 shares of RegenxbioSEC Form 46 January 2026Common Stock · traded 2 January 2026 · filed 6 January 2026
- had shares withheld for tax on 5,263 shares of RegenxbioSEC Form 44 April 2025Common Stock · traded 1 February 2025 · filed 4 April 2025
- was granted 103,698 shares of Regenxbio (a derivative holding)SEC Form 46 January 2025Stock Options (Right to buy) · traded 2 January 2025 · filed 6 January 2025
- had shares withheld for tax on 13,891 shares of RegenxbioSEC Form 46 January 2025Common Stock · traded 2 January 2025 · filed 6 January 2025
- was granted 64,293 shares of RegenxbioSEC Form 46 January 2025Common Stock · traded 2 January 2025 · filed 6 January 2025
- was granted 58,386 shares of RegenxbioSEC Form 45 August 2024Common Stock · traded 1 August 2024 · filed 5 August 2024
- exercised options over 12,878 shares of Regenxbio (a derivative holding)SEC Form 47 March 2024Stock Options (Right to Buy) · traded 5 March 2024 · filed 7 March 2024
- exercised options over 12,878 shares of RegenxbioSEC Form 47 March 2024Common Stock · traded 5 March 2024 · filed 7 March 2024
- ▼ sold on the open market 12,878 shares of RegenxbioSEC Form 47 March 2024Common Stock · traded 5 March 2024 · filed 7 March 2024
- was granted 50,875 shares of Regenxbio (a derivative holding)SEC Form 44 January 2024Stock Options (Right to buy) · traded 2 January 2024 · filed 4 January 2024
- had shares withheld for tax on 10,385 shares of RegenxbioSEC Form 44 January 2024Common Stock · traded 2 January 2024 · filed 4 January 2024
- was granted 32,051 shares of RegenxbioSEC Form 44 January 2024Common Stock · traded 2 January 2024 · filed 4 January 2024
- ▼ sold on the open market 17,237 shares of RegenxbioSEC Form 44 January 2024Common Stock · traded 3 January 2024 · filed 4 January 2024
- was granted 44,155 shares of Regenxbio (a derivative holding)SEC Form 45 January 2023Stock Options (Right to buy) · traded 3 January 2023 · filed 5 January 2023
- had shares withheld for tax on 1,837 shares of RegenxbioSEC Form 45 January 2023Common Stock · traded 3 January 2023 · filed 5 January 2023
- ▼ sold on the open market 3,138 shares of RegenxbioSEC Form 45 January 2023Common Stock · traded 3 January 2023 · filed 5 January 2023
- was granted 90,588 shares of RegenxbioSEC Form 45 January 2023Common Stock · traded 3 January 2023 · filed 5 January 2023
- was granted 42,500 shares of Regenxbio (a derivative holding)SEC Form 44 January 2022Stock Option (Right to Buy) · traded 3 January 2022 · filed 4 January 2022
- had shares withheld for tax on 1,152 shares of RegenxbioSEC Form 44 January 2022Common Stock · traded 1 January 2022 · filed 4 January 2022
- ▼ sold on the open market 1,598 shares of RegenxbioSEC Form 44 January 2022Common Stock · traded 3 January 2022 · filed 4 January 2022
- was granted 8,900 shares of RegenxbioSEC Form 44 January 2022Common Stock · traded 3 January 2022 · filed 4 January 2022
- was granted 11,000 shares of RegenxbioSEC Form 46 January 2021Common Stock · traded 4 January 2021 · filed 6 January 2021
- was granted 49,700 shares of Regenxbio (a derivative holding)SEC Form 46 January 2021Stock Option (Right to Buy) · traded 4 January 2021 · filed 6 January 2021
- was granted 42,600 shares of Regenxbio (a derivative holding)SEC Form 46 January 2020Stock Option (Right to Buy) · traded 2 January 2020 · filed 6 January 2020
- was granted 95,000 shares of Regenxbio (a derivative holding)SEC Form 419 April 2019Stock Option (Right to Buy) · traded 17 April 2019 · filed 19 April 2019
- was granted 125,000 shares of Aerpio Pharmaceuticals (a derivative holding)SEC Form 420 February 2019Stock Option (Right to Buy) · traded 15 February 2019 · filed 20 February 2019
- was granted 100,000 shares of Aerpio Pharmaceuticals (a derivative holding)SEC Form 425 April 2018Stock Option (Right to Buy) · traded 23 April 2018 · filed 25 April 2018
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.